

*Place:* Wyndham Washington, DC, 1400 M Street, NW., Washington, DC 20005.

*Contact Person:* Ellen K. Schwartz, PhD, EDD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3168, MSC 7770, Bethesda, MD 20892, (301) 435-0681.

*Name of Committee:* Social Sciences, Nursing, Epidemiology and Methods Integrated Review Group, Social Sciences, Nursing, Epidemiology and Methods 2.

*Date:* February 27–28, 2003.

*Time:* 9 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

*Contact Person:* Yvette Davis, VMD, MPH, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3152, MSC 7770, Bethesda, MD 20892, (301) 435-0906.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Alpha Adrenergic Signaling.

*Date:* February 27, 2003.

*Time:* 1 p.m. to 1:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Latham Hotel, 300 M Street, NW., Washington, DC 20007.

*Contact Person:* Anshumali Chaudhari, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4124, MSC 7802, Bethesda, MD 20892, (301) 435-1210.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, ZRG1 SSS T: 10B: Small Business: Endocrinology, Metabolism, Nutrition, & Reproductive Sciences.

*Date:* February 27–28, 2003.

*Time:* 7 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Krish Krishnan, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6164, MSC 7892, Bethesda, MD 20892, (301) 435-1041.

*Name of Committee:* Biophysical and Chemical Sciences Integrated Review Group, Metallobiochemistry Study Section.

*Date:* February 28, 2003.

*Time:* 8:30 a.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Phoenix Park Hotel, 520 North Capitol Street, Washington, DC 20001.

*Contact Person:* Janet Nelson, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4168, MSC 7806, Bethesda, MD 20892, (301) 435-1723, [nelsonja@csr.nih.gov](mailto:nelsonja@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Adverse Drug Reactions.

*Date:* February 28, 2003.

*Time:* 11 a.m. to 1 p.m.

*Agenda:* To review and evaluate cooperative agreement applications.

*Place:* Latham Hotel, 3000 M Street, NW., Washington, DC 20007.

*Contact Person:* Joyce C. Gibson, DSC, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4172, MSC 7804, Bethesda, MD 20892, (301) 435-4522, [gibsonj@csr.nih.gov](mailto:gibsonj@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

*Dated:* February 6, 2003.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 03–3625 Filed 2–13–03; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, February 10, 2003, 8 a.m. to February 10, 2003, 4 p.m., which was published in the **Federal Register** on January 29, 2003, 68 FR 4501–4503.

The meeting will be two days February 9–10, 2003, from 7:30 p.m. to 4 p.m. The location remains the same. The meeting is closed to the public.

*Dated:* February 6, 2003.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 03–3626 Filed 2–13–03; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes Of Health

#### Prospective Grant of Exclusive License: Vaccines Against Rotavirus Disease

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating

the grant of an exclusive world-wide license to practice the invention embodied USPN 4,704,275, USPN 4,751,080 (“Vaccine Against Rotavirus Disease”) and USPN 4,571,385 (“Genetic Re-assortment Of Rotaviruses For Production Of Vaccines And Vaccine Precursors”) and foreign patent applications or other related materials to BIOVIRx, Inc. of Shoreview, MN. The rights to this invention have been assigned to the United States of America.

**DATES:** Only written comments and/or applications for a license which are received by NIH on or before April 15, 2003 will be considered.

**ADDRESSES:** Requests for a copy of a license application, inquiries, comments and other materials relating to the contemplated license should be directed to: Steven M. Ferguson, Deputy Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852; Telephone: (301) 435–5561; Facsimile: (301) 402–0220; E-mail: [sf8h@nih.gov](mailto:sf8h@nih.gov).

**SUPPLEMENTARY INFORMATION:** U.S. Patents 4,704,275 and 4,751,080 describe a live, attenuated serotype 3 rhesus rotavirus (or reassortments thereof) suitable for prevention of rotavirus disease in humans. U.S. Patent 4,571,385 describes methods of producing a human rotavirus vaccine based upon the re-assortment of human and non-human rotavirus strains.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license may be limited to the field of immunoprophylactic protection against rotavirus disease.

This prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.